Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease

ConclusionsAlthough consistent efficacy of spironolactone was observed across the range of eGFR, the risk of AEs was amplified in the lower eGFR categories. These data supported use of spironolactone to treat HFpEF patients with advanced chronic kidney disease only when close laboratory surveillance is possible.Graphical abstract
Source: JACC: Heart Failure - Category: Cardiology Source Type: research